Hetaryloxy-substituted phenylamino pyrimidines as Rho kinase inhibitors

US8329716B2 · kind B2 · utility

Assignee

• Bayer Intellectual Property GmbH · DE

Inventors

• Hartmut Schirok · Wuppertal, DE
• Martin Radtke · Erkrath, DE
• Joachim Mittendorf · Wuppertal, DE
• Raimund Kast · Wuppertal, DE
• Johannes-Peter Stasch · Wuppertal, DE
• Mark Jean Gnoth · Mettmann, DE
• Klaus Münter · Mannheim, DE
• Dieter Lang · Velbert, DE
• Santiago Figueroa Perez · Leverkusen, DE
• Michael Thutewohl · Buchs, CH
• Samir Bennabi · Wuppertal, DE
• Heimo Ehmke · Hamburg, DE

Key dates

• Filing date: Mar 30, 2005
• Grant date: Dec 11, 2012
• Expiry date: Jul 20, 2027

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to hetaryloxy-substituted phenylaminopyrimidines, to a process for their preparation and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases in humans and animals, in particular cardiovascular disorders.